BIG-NCTN
A large international research effort
Global collaboration to
We believe that global collaboration is crucial to making significant advances in breast cancer research: reducing unnecessary duplication of effort, sharing data, enabling collaboration of scientists across borders, contributing to the faster development of better treatments, and increasing the likelihood of cures for patients.
Thanks to the generous and exclusive support of the Breast Cancer Research Foundation, BIG and the NCI National Clinical Trials Network (NCTN) – the latter a network of major US and Canadian-based research groups supported by the US National Cancer Institute (NCI) – have been meeting annually and in topic-specific working groups since 2005.
advance breast cancer research
Together they identify difficult and unresolved aspects of breast cancer treatment and care, focus on research areas not supported by the pharmaceutical industry, and collaborate to set up large international research programmes that always put patients’ need first.
BIG and NCTN experts are working together in topic-specific working groups throughout the year, and they meet annually in June. This collaboration was initiated by Martine Piccart and William Wood, co-Chairs of the first meetings, in partnership with Larry Norton (BCRF) and JoAnne Zujewski (NCI).
Male Breast Cancer Programme
Characterising male breast cancer in order to improve treatments.
POSITIVE
Pregnancy outcomes and safety of interrupting endocrine therapy for young women with ER+ breast cancer.
Together, BIG and NCTN strive to improve the care and cure rates of patients with breast cancer through international collaboration
| Year | Title | Authors | Reference |
|---|---|---|---|
|
2020 |
Road Map to Safe and Well-Designed De-escalation Trials of Systemic Adjuvant Therapy for Solid Tumors |
Piccart M, Hilbers F, Bliss J et al. |
|
|
2017 |
Male breast cancer precursor lesions: analysis of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program |
Doebar SC, Slaets L, Cardoso F et al. |
|
|
2017 |
Pathological characterisation of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program |
Vermeulen MA, Slaets L, Cardoso F et al. |
|
|
2015 |
Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration |
Bossuyt V, Provenzano E, Symmans WF et al. |
|
|
2015 |
Standardization of pathologic evaluation and reporting of post-neoadjuvant specimens in clinical trials of breast cancer: Recommendations from an international working group |
Provenzano E, Bossuyt V, Viale G et al. |
|
|
2015 |
Defining Breast Cancer Intrinsic Subtypes by Quantitative Receptor Expression |
Cheang MC, Martin M, Nielsen TO et al. |
|
|
2015 |
An international study to increase concordance in Ki67 scoring |
Polley MY, Leung SC, Gao D et al. |
|
|
2013 |
An International Ki67 Reproducibility Study |
Polley MC, Leung SCY, McShane LM et al. |
|
|
2013 |
Perceptions and needs of women with metastatic breast cancer: A focus on clinical trials |
Nahleh ZA, Lin NU, Wolff AC et al. |
|
|
2012 |
A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints |
Fumagalli D, Bedard PL, Nahleh Z et al. |
|
|
2011 |
Pregnancy after breast cancer: if you wish, ma'am |
Pagani O, Partridge A, Korde et al. |
|
|
2011 |
Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen types |
Loi S, Symmans WF, Bartlett J et al. |
|
|
2008 |
Recommendations for collection and handling of specimens from group breast cancer clinical trials |
Leyland‐Jones BR, Ambrosone CB, Bartlett JMS et al. |
